Free Trial
→ Move $1,000 into this stock before Nov 6 (From Altimetry) (Ad)tc pixel

Weiss Ratings Reiterates Sell (E+) Rating for Coeptis Therapeutics (NASDAQ:COEP)

Written by MarketBeat
October 25, 2025
Coeptis Therapeutics logo with Medical background

Key Points

  • Weiss Ratings has reiterated a "sell (e+)" rating for Coeptis Therapeutics (NASDAQ: COEP), signaling continued investor caution regarding the stock.
  • Coeptis Therapeutics experienced a 5.4% decrease in stock price on Friday, closing at $15.00 amid a trading volume of 56,988 shares.
  • The company's most recent quarterly report showed a significant loss, with earnings per share of ($1.17) and revenue of only $0.20 million.
  • Five stocks to consider instead of Coeptis Therapeutics.

Coeptis Therapeutics (NASDAQ:COEP - Get Free Report)'s stock had its "sell (e+)" rating reissued by Weiss Ratings in a research report issued to clients and investors on Friday,Weiss Ratings reports.

Coeptis Therapeutics Trading Down 5.4%

COEP traded down $0.85 during trading on Friday, reaching $15.00. The company had a trading volume of 56,988 shares, compared to its average volume of 44,090. The stock has a market cap of $72.30 million, a P/E ratio of -2.59 and a beta of -0.49. The business has a 50 day simple moving average of $14.60 and a 200-day simple moving average of $11.30. Coeptis Therapeutics has a 52 week low of $2.31 and a 52 week high of $19.19. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 0.02.

Coeptis Therapeutics (NASDAQ:COEP - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($1.17) earnings per share for the quarter. The business had revenue of $0.20 million for the quarter.

Coeptis Therapeutics Company Profile

(Get Free Report)

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Coeptis Therapeutics Right Now?

Before you consider Coeptis Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coeptis Therapeutics wasn't on the list.

While Coeptis Therapeutics currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.